...
首页> 外文期刊>The Indian journal of medical research. >Molecular description of plasmid-mediated AmpC β-lactamases among nosocomial isolates of Escherichia coli & Klebsiella pneumoniae from six different hospitals in India
【24h】

Molecular description of plasmid-mediated AmpC β-lactamases among nosocomial isolates of Escherichia coli & Klebsiella pneumoniae from six different hospitals in India

机译:来自印度六家不同医院的大肠杆菌和肺炎克雷伯菌的医院分离株中质粒介导的AmpCβ-内酰胺酶的分子描述

获取原文
获取原文并翻译 | 示例

摘要

Background & objectives: Plasmid mediated AmpC β-lactamase (PMABL) resistance in Escherichia coli and Klebsiella spp. is an emerging problem worldwide. Phenotypic methods are commonly used for detection of PMABL production in Gram-negative isolates, but molecular data about the prevalence of plasmid-mediated AmpC-type resistance at the national level are needed. Hence, a prospective study was undertaken to determine the occurrence of PMABL gene and its types among clinical isolates of E. coli and K. pneumoniae obtained from six different hospitals in India. Methods: A total of 241 nosocomial isolates of K. pneumoniae (n=109) and E.coli (n=132) from six geographically distant hospitals in India were included. These were screened for cefoxitin resistance. AmpC disk test and modified three dimensional extraction test were used for phenotypic detection of PMABL production. Molecular types were determined by a multiplex PCR. Results: Among the 241 isolates, 187 (77.5%) were found to be cefoxitin resistant (K. pneumoniae n=83, E. coli n=104). AmpC activity was detectable in 153 (63.4%) isolates, (K. pneumoniae n=69, E. coli n=84). By PCR, the plasmid encoded AmpC genes were found in 92 (38.1%) isolates and the molecular types of the genes detected predominantly were DHA, CIT followed by MOX and ACC types. Interpretation & conclusions: A high percentage of plasmid-encoded AmpC enzymes was noted in E. coli and K. pneumonia isolates obtained from different parts of the country. Phenotypic methods alone may not reflect the true number of PMABL producers. Genotypic methods need to be employed in national surveillance studies.
机译:背景与目的:质粒介导的大肠埃希菌和克雷伯菌属的AmpCβ-内酰胺酶(PMABL)抗性。是全球范围内一个新兴问题。表型方法通常用于检测革兰氏阴性菌中PMABL的产生,但是需要有关国家一级质粒介导的AmpC型抗性流行率的分子数据。因此,进行了一项前瞻性研究,以确定从印度六家不同医院获得的大肠杆菌和肺炎克雷伯氏菌临床分离株中PMABL基因的发生及其类型。方法:包括印度六所地理位置较远的医院的共241例肺炎克雷伯菌(n = 109)和大肠杆菌(n = 132)的医院分离株。筛选这些药物对头孢西丁的耐药性。 AmpC磁盘测试和改进的三维提取测试用于PMABL生产的表型检测。分子类型通过多重PCR确定。结果:在241株分离株中,发现有187株(77.5%)对头孢西丁耐药(肺炎克雷伯氏菌n = 83,大肠杆菌n = 104)。在153个(63.4%)分离株中检测到AmpC活性(肺炎克雷伯氏菌n = 69,大肠杆菌n = 84)。通过PCR,在92个(38.1%)分离物中发现了编码AmpC基因的质粒,检测到的基因的分子类型主要是DHA,CIT,然后是MOX和ACC类型。解释与结论:从该国不同地区获得的大肠杆菌和肺炎克雷伯菌分离株中发现有很高百分比的质粒编码AmpC酶。仅表型方法可能无法反映PMABL生产者的真实数量。国家监测研究中需要采用基因型方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号